Amresh Raina, MD, is director of the Advanced Heart Failure and Pulmonary Hypertension Program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania.
Amresh Raina, MD, is director of the advanced heart failure and pulmonary hypertension program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania. He is board-certified in advanced heart failure, echocardiography (imaging of the right ventricle), and general cardiology.
Transcript
How do the pathophysiologies of heart failure and chronically elevated pulmonary pressure intersect?
That’s a very interesting question. Pulmonary hypertension, first of all, is a broad term, saying that the pulmonary artery pressures—the pressures in the blood vessels of the lungs—are elevated, but doesn’t really say why they’re elevated. And so the first thing to note is that there are multiple different reasons and pathophysiologies at work in the development of pulmonary hypertension.
There are specific forms of pulmonary hypertension that are related to elevated resistance in the blood vessels of the lungs, and those are pulmonary arterial hypertension—we call that WHO [World Health Organization] Group 1, as well as chronic thromboembolic pulmonary hypertension, [and] that’s WHO Group 4. Those are diseases that lead to elevation and resistance in the blood vessels of the lungs, narrowing and constriction of the blood vessels. That elevates the pulmonary artery pressures, but also causes the right side of the heart to have to work harder to overcome that resistance and those pressures. And that can lead to right-sided congestive heart failure, symptoms of shortness of breath, swelling in the lower extremities, etc.
However, there are other forms of congestive heart failure that can cause pulmonary hypertension. Patients who have left-sided congestive heart failure, whether that’s due to lower left ventricular ejection fraction—what we call heart failure with reduced ejection fraction—or in patients who have heart failure symptoms but preserved left ventricular ejection fraction, both of those entities can cause elevation in pressures on the left side of the heart and that pressure can back up into the lungs and cause secondary pulmonary hypertension. That’s a different group of pulmonary hypertension, which we call related to left heart disease or WHO Group 2.
So, pulmonary hypertension can be the disease in and of itself, impacting the right side of the heart, or it can be a manifestation of a left-sided heart problem.
Dr. Raina is a nationally renowned physician with expertise in the diagnostic evaluation and management of pulmonary hypertension. His particular interest is in advanced imaging of the right ventricle in pulmonary arterial hypertension. He has published extensively in this field, with numerous peer-reviewed manuscripts, abstracts, and book chapters. Dr. Raina was named one of Pittsburgh Magazine's "Best Doctors" in 2019.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More